How does older age influence oncologists' cancer management?

BACKGROUND Over half of new cancer cases occur in patients aged > or = 65 years. Many older patients can benefit from intensive cancer therapies, yet evidence suggests that this population is undertreated. METHODS To assess preferences and influential factors in geriatric cancer management, practicing U.S. medical oncologists completed a survey containing four detailed vignettes exploring colon, breast, lung, and prostate cancer treatment. Participants were randomly assigned one of two surveys with vignettes that were identical except for patient age (<65 years or >70 years). RESULTS Physicians in each survey group (n = 200) were demographically similar. Intensive therapy was significantly less likely to be recommended for an older than for a younger, but otherwise identical, patient in two of the scenarios. For a woman with metastatic colon cancer (Eastern Cooperative Oncology Group [ECOG] score, 1) for whom chemotherapy was recommended, nearly all oncologists chose an intensive regimen if the patient's age was 63; but if her age was 85, one fourth of the oncologists chose a less intensive treatment. Likewise, for stage IIA breast cancer (ECOG score, 0), 93% recommended intensive adjuvant treatment for a previously healthy patient aged 63; but only 66% said they would do so if the patient's age was 75. Oncologists commonly identified patient age as an influence on treatment choice, but were even more likely to cite performance status as a determining factor. CONCLUSIONS Advanced age can deter oncologists from choosing intensive cancer therapy, even if patients are highly functional and lack comorbidities. Education on tailoring cancer treatment and a greater use of comprehensive geriatric assessment may reduce cancer undertreatment in the geriatric population.

[1]  A. Naeim,et al.  Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Ettinger,et al.  Radiotherapy patterns of care study in lung carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Walter,et al.  Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.

[4]  T. Lash,et al.  Breast cancer treatment of older women in integrated health care settings. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Hudis,et al.  Factors influencing treatment patterns of breast cancer patients age 75 and older. , 2003, Critical reviews in oncology/hematology.

[6]  L. Clegg,et al.  Patterns of Care for Adjuvant Therapy in a Random Population-Based Sample of Patients Diagnosed with Colorectal Cancer , 2006, The American Journal of Gastroenterology.

[7]  M. Weinstein,et al.  Impact of referral patterns on the use of chemotherapy for lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Thigpen Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy , 2008 .

[9]  M. Extermann,et al.  Comprehensive geriatric assessment for older patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Hurria Clinical trials in older adults with cancer: past and future. , 2007, Oncology.

[11]  E. Elkin,et al.  Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Langer Neglected and underrepresented subpopulations: elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer. , 2006, Clinical lung cancer.

[13]  E. Gore,et al.  Age Is Independent of Comorbidity Influencing Patient Selection for Combined Modality Therapy for Treatment of Stage III Nonsmall Cell Lung Cancer (NSCLC) , 2006, American journal of clinical oncology.

[14]  Thomas O. Blank,et al.  A gerontologic perspective on cancer and aging , 2008, Cancer.

[15]  S. Sternberg THE VULNERABLE ELDERS SURVEY: A TOOL FOR IDENTIFYING VULNERABLE OLDER PEOPLE IN THE COMMUNITY , 2003, Journal of the American Geriatrics Society.

[16]  J. Goodwin,et al.  Use and outcomes of adjuvant chemotherapy in older women with breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Lachs,et al.  Geriatric assessment for oncologists: rationale and future directions. , 2006, Critical reviews in oncology/hematology.

[18]  R. Beart,et al.  Rates and predictors of chemotherapy use for stage III colon cancer , 2008, Cancer.

[19]  V. Lawrence,et al.  Cancer rates, medical comorbidities, and treatment modalities in the oldest patients. , 2008, Critical reviews in oncology/hematology.

[20]  H. Bartelink,et al.  Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. , 2007, The Lancet. Oncology.

[21]  C. Bokemeyer,et al.  Tolerance to chemotherapy in elderly patients with cancer. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[22]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[23]  D. Gandara,et al.  Chemotherapy in patients ≥ 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6 , 2005 .

[24]  J. Peppercorn Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience , 2008 .

[25]  C. Earle,et al.  Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. , 2009, Journal of the American College of Surgeons.

[26]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Robert B Wallace,et al.  Population variations in the initial treatment of non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Kris,et al.  Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients , 2006, Clinical Cancer Research.

[29]  Joy H. Lewis,et al.  Participation of patients 65 years of age or older in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Vlastos,et al.  Older female cancer patients: importance, causes, and consequences of undertreatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Leake,et al.  Health care disparities in older patients with breast carcinoma , 2003, Cancer.

[32]  K. Kahn,et al.  Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Diane Podsiadlo,et al.  The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons , 1991, Journal of the American Geriatrics Society.

[34]  D. Tripathy Adjuvant chemotherapy in Older Women with Early-Stage Breast Cancer , 2010 .